UOC
CRSP icon

UBS O'Connor’s CRISPR Therapeutics CRSP Stock Holding History

UBS O'Connor’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$27.3K – 336
2025
Q2 		$27.3K Buy
+10,000
New +$387K ﹤0.01% 333
2025
Q1 		– Sell
-20,000
Closed -$4K – 387
2024
Q4 		$4K Sell
20,000
-10,000
-33% -$472K ﹤0.01% 407
2024
Q3 		$63.8K Buy
30,000
+5,000
+20% +$254K ﹤0.01% 422
2024
Q2 		$4.38K Buy
25,000
+9,000
+56% +$521K ﹤0.01% 524
2024
Q1 		$10.8K Buy
16,000
+1,000
+7% +$71.6K ﹤0.01% 488
2023
Q4 		$15K Buy
+15,000
New +$829K ﹤0.01% 452

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return